Immunoassay for quantitative determination of human proinsulin in serum or plasma.
Read the Directions for Use
Related products: Sample buffer (for dilution of samples when needed) 10-1195-01
10-1134-01 Control, Diabetes antigen - Human Low and High (unassayed - US only)
Mercodia Proinsulin ELISA provides a method for the quantitative determination of human proinsulin in serum or plasma.
Format: 1 x 96 wells
Specificity: No crossreactivity to insulin or C-peptide.
Samples: Serum, plasma
Sample volume: 50 μL
Assay range: 3.3 - 132 pmol/L
Detection limit: ≤ 0.5 pmol/L (0.0045 μg/L)
Incubation (min): 60+60+15
The detection limit is 0.5 pmol/L calculated as two standard
deviations above the Calibrator 0.
Recovery upon addition is 97 %. Each sample was analyzed in 4 replicates on 7 different occasions
|Sample||Mean Value||Coefficient of variation|
|(μg/L)||within assay %||between assay %||total assay %|
Serum, EDTA, heparin and citrate plasma can be used. Sample volume: 25 μL.
Grossly lipemic, icteric or haemolyzed samples do not interfere
in the assay.
Mercodia Proinsulin ELISA is a solid phase two-site enzyme immunoassay based on the sandwich technique, in which two monoclonal antibodies are directed against separate antigenic determinants on the proinsulin molecule. Proinsulin in the sample reacts with anti-proinsulin antibodies bound to microtitration wells and peroxidase-conjugated anti-insulin antibodies in the solution
Summary of protocol
The following cross-reactions have been tested:
|Insulin||< 0.03 %|
|C-peptide||< 0.006 %|
|Proinsulin (Des 31-32)||95 %|
|Proinsulin (Split 32-33)||95 %|
|Proinsulin (Des 64-65)||84 %|
|Proinsulin (Split 65-66)||90 %|
Analysis of insulin, C-peptide or proinsulin from acid ethanol extractions from islets, cells or tissue.pdf
The cross reaction of Proinsulin metabolites in the Mercodia Proinsulin ELISA assay.pdf
Instand proinsulin survey.pdf
Instruction manual wash.pdf
Instruction for test of microplate reader.pdf
AlEssa, H. B. et al. Dietary patterns and cardiometabolic and endocrine plasma biomarkers in US women. Am. J. Clin. Nutr. 105, 432–441 (2017).
Derosa, G, Ragonesi, P, D (2012)
Vildagliptin Added to Metformin on beta-Cell Function After a Euglycemic Hyperinsulinemic and Hyperglycemic Clamp in Type 2 Diabetes Patients
Iggman, D, Rosqvist, F, Larsson, A (2014)
Role of dietary fats in modulating cardiometabolic risk during moderate weight gain: a randomized double-blind overfeeding trial (LIPOGAIN study)
Fraser, A, Nelson, S, M (2012)
Associations of pregnancy complications with calculated cardiovascular disease risk and cardiovascular risk factors in middle age: the Avon Longitudinal Study of Parents and Children